Home
Recent press, briefings and insights helping you stay informed on AliveDx newest launch.
Received feedback from the European notified body after review of Expanded IH submission Pleased with feedback and expect to submit a response to the questions in the next couple of weeks Continue to expect approval in Q1 CY 2022
“It is my pleasure to welcome Esteban to the Executive team at this exciting time in our Company’s evolution. Esteban brings his experience in leading high-growth teams and unifying manufacturing and supply chain management. As we transition the company from
“I am delighted to welcome Ali to the Executive team at this exciting time in our Company’s evolution. He brings over 20 years of experience in global finance and has been a key driver of operational excellence in a career
“I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of
JERSEY, Channel Islands, 1 October 2021 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the launch of the review process of the Expanded Immunohematology (IH) technical file dossier for review by the European notified
MosaiQ is designed to deliver rapid immunohematology, serological and molecular disease screening, using a single low volume sample on a high throughput, multimodal multiplexing automated platform. MosaiQ represents a transformative and potentially highly disruptive unified testing system for transfusion diagnostics
“We are very confident, that Manuel is the right leader”, said Heino von Prondzynski, Chairman of Quotient’s Board of Directors. “His background and experience make him ideally suited to guide the Company through its very important next phase, commercialization of
JERSEY, Channel Islands, 12 January 2021(GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has been named a winner in the prestigious 2021 BIG Innovation Awards presented by the Business Intelligence Group. The annual
Expanded IH Microarray Preliminary Performance To date in the EU field trial, over 4000 randomly selected human blood donor samples have been tested. The concordance data obtained through the study are as follows: Antigen Type A B D C c E e
The study was conducted at an independent laboratory using over 500 samples. The MosaiQ COVID-19 Antibody Microarray detects two types of antibodies produced in response to SARS-CoV-2 infection–IgM and IgG antibodies. A test that detects both types of antibodies provides